Potential candidates to be added:
$TTD (+1.07%) The Trade Desk
$HOOD (+2.92%) Robinhood
$COIN (+1.61%) Coinbase
$APP (+4.95%) Applovin
Potential candidates to be removed:
$WBA (+0.14%) Walgreens
$INTC (+7.46%) Intel
Posts
55Potential candidates to be added:
$TTD (+1.07%) The Trade Desk
$HOOD (+2.92%) Robinhood
$COIN (+1.61%) Coinbase
$APP (+4.95%) Applovin
Potential candidates to be removed:
$WBA (+0.14%) Walgreens
$INTC (+7.46%) Intel
$WBA (+0.14%) WALGREENS BOOTS ALLIANCE TO BE ACQUIRED BY SYCAMORE PARTNERS IN A DEAL WORTH UP TO USD 23.7 BILLION; SHAREHOLDERS TO RECEIVE USD 11.45 PER SHARE IN CASH $WBA
Everyone only ever shows their winners, but let's be honest - that's boring.
I'm going to turn the tables and present you with my own personal financial disasters. Because who diamond hands need a thick skin.
My investment strategy?
Here are my highlights from the "Let's burn down the portfolio!"-category:
Intel (-41%) $INTC (+7.46%)
I thought I was buying a solid chip giant. Turns out: I bought a museum walk through the glory days of 1995. While Nvidia is flying to the moon, Intel is barely keeping its head above water like an old Windows 98 computer.
Unity Software (-68%) $U (+1.56%)
"Gaming is the future! Unity is THE platform for developers!" - At least that's what I thought. In reality, Unity has bugged itself so badly that not even a game patch would help. At least I have the consolation that my shares are more lag than a mobile game with too much advertising.
Walgreens Boots Alliance (-77%) $WBA (+0.14%)
Pharmacies? Safe bet! People always get sick! It's just stupid when a company is managed in such a way that even a pharmaceutical giant looks like it has overdosed itself.
Compass Pathways (-88%) $5Y6A
Psychedelic therapy is the future! Or so I thought. But my investment journey was more like a wild drug trip that ended directly in the financial hole. Instead of astral travel, it was just capital destruction.
Edita's Medicine (-95%) $EDIT (-0.48%)
Genetic engineering and CRISPR? Technology of the future! It's just a shame that my investment was deleted faster than faulty DNA. Editas has actually managed to edit itself out - and my capital along with it.
And you?
Do you also have a "Loss P0rn" story you want to share?
Or are you smarter than me and use stop losses? 😂
In the following post, I would like to discuss the new US tariffs and their potential economic consequences. The background and the potential impact on inflation and companies, as well as the winners and losers on the stock market, will be discussed.
Again, of course, the stocks mentioned do not constitute investment advice, but merely serve as examples of possible beneficiaries or losers of tightening trade restrictions. Historical developments are no guarantee of future returns.
__________
In this post:
__________
The topic of "tariffs" is currently not only very present in the media, but the term "tariffs" has also been discussed with a strong increase in the past earnings calls of companies in the S&P 500, as the following chart shows [1].
The chart shows that the discussion about tariffs has intensified in recent months and is having an ever greater impact on the outlook in companies' annual reports.
The data is presented as a three-month average and broken down into various sectors, including e.g. industry, healthcare, consumer goods, information technology, etc.
I am curious to see how the stock markets will behave in the coming week. In addition to the current reporting season, the topic of "tariffs" will certainly dominate.
After the tough tariffs announced after Trump took office were not immediately enforced and there was a "slight" sigh of relief, there could now be a new reaction on the markets, as there was on Friday evening. slightly was already slightly noticeable on Friday evening when the markets turned towards the evening.
A looming trade conflict could not only affect individual companies, but also further fuel inflation in the US:
💰 Influence on inflation
On January 31, Deutsche Bank published a forecast on the potential impact of tariffs on the inflation rate [2]:
The chart compares the current forecast with the forecast before the "Trump" era and takes into account various scenarios for the passing on of tariffs (pass-through) by Canada and Mexico.
Two scenarios are considered: one with a 50% pass-through of tariffs (additional increase shown in dark green) and one with a 75% pass-through (light green). It is clear that the inflation rate could rise sharply again this year and fall again by 2027.
🛃 New tariffs in force & further measures planned
As of today, February 1, 2025, the US government and Donald Trump have imposed new import tariffs on Mexico, Canada and China:
According to the White House spokesperson, these measures are, among other things, a response to the failure of these countries to stop the influx of fentanyl and illegal immigrants into the USA. [3]
But this is just the beginning:
From mid-February, the USA will also impose tariffs on strategic goods [4], including:
🚨 Trump relies on escalation - Canada announces retaliation
Yesterday, Canadian government representatives, including Foreign Minister Mélanie Joly, tried to prevent the tariffs in Washington, but to no avail.
Trump made it clear before his departure to Mar-a-Lago [5]:
"We have a 200 billion dollar trade deficit with Canada. Why should we subsidize Canada?"
The EU could also soon be targeted, as Trump hinted:
"Absolutely! The European Union has treated us so terribly!"
🔄 Canada's reaction:
Prime Minister Justin Trudeau announced that Canada will not back down and will respond with "swift and robust countermeasures".
The government is planning a three-stage retaliation strategy [5]:
However, this last step in particular would be a double-edged sword, as Canada is heavily dependent on energy cooperation with the USA.
Economic experts in the US are already warning of the consequences of a trade war [5]:
But Trump remains firm:
"Maybe there will be short-term disruption, but in the long run the tariffs will make us very rich and very strong."
🌎 Possible consequences for the global economy
(a) Rising prices in the USA
(b) Retaliation & new trade wars?
(c) Effects on the stock market
🏆 Winners & losers - which companies will benefit, which will suffer?
Possible beneficiaries of the tariffs
US manufacturers of steel, aluminum & copper
Domestic pharmaceutical and biotech companies
Energy companies with US production
Chip manufacturers with US production
😥 Companies that could suffer from the tariffs
Chip manufacturers with global supply chains
Car manufacturers with global suppliers
Companies with strong export business
US retailers with a high import share
🧠 Possible investment strategies
Favor defensive sectors:
Exploit long-term opportunities in "reshoring":
Conclusion: Will the trade conflict escalate further?
With the new tariffs, Trump is taking a confrontational stance and Canada, Mexico and China are preparing for retaliatory measures. If further tariffs on European goods follow, the situation could worsen.
❓Which stocks do you think could be most affected? Which beneficiaries do you see?
Thanks for reading! 🤝
__________
Sources:
[4]
[5] https://www.tagesschau.de/ausland/amerika/usa-trump-strafzoelle-100.html
🔹 Adj EPS: $0.51 (Est. $0.38) 🟢
🔹 Revenue: $39.46B (Est. $37.34B) 🟢; UP +7.5% YoY
🔹 International Sales: $6.43B (Est. $5.9B) 🟢; UP +10.2% YoY
🔹 U.S. Retail Pharmacy Sales: $30.87B (Est. $29.16B) 🟢; UP +6.6% YoY
Guidance
🔹 FY 2025 Adjusted EPS: $1.40-$1.80 (Est. $1.53)🟢
Q1 Segment Performance
U.S. Retail Pharmacy
🔹 Sales: $30.87B; UP +6.6% YoY
🔹 Comparable Sales: UP +8.5% YoY
🔹 Pharmacy Sales: UP +10.4% YoY
🔹 Comparable Retail Sales: DOWN -4.6% YoY
International
🔹 Sales: $6.43B; UP +10.2% YoY (UP +6.5% on a constant currency basis)
🔹 Boots UK Comparable Pharmacy Sales: UP +10.9% YoY
🔹 Boots UK Comparable Retail Sales: UP +8.1% YoY
🔹 Boots. com Sales: UP +30% YoY
U.S. Healthcare
🔹 Sales: $2.17B; UP +12.5% YoY
🔹 Adjusted Operating Income: $25M (vs. Loss of $96M YoY) 🟢
🔹 Adjusted EBITDA: $70M (Improved from -$39M YoY) 🟢
Other Metrics:
🔹 Comparable Pharmacy Sales: UP +12.7% YoY
🔹 Adjusted Operating Income: $593M; DOWN -13.7% YoY
CEO Tim Wentworth's Commentary
🔸 “Our Q1 results reflect disciplined execution and progress on our strategic priorities, including stabilizing retail pharmacy and improving cash flow. While the turnaround will take time, early progress reaffirms our confidence in a sustainable, pharmacy-led operating model.”
My development in this area has been very mixed. After I sold in December $WBA (+0.14%) after a risky purchase - to lower the buy in - with +/- 0, my investment in $AFX (-2.03%) was abruptly terminated, leaving me with a hefty loss, and shortly afterwards I unfortunately also lost my shares in $UNH (+0.61%) but still with a profit of 8%. Today I decided to recoup my losses and sold my $BMY (-0.61%) sold. It was a nice trade, plus the €245 dividend plus the payment on February 3rd. The uncertainty in the sector has become too great for me and I want to watch from the sidelines what the new US government will do. Marty Makary as the planned head of the FDA will certainly not strike as brutally as some fear, but there could be changes and difficulties in the area of approval procedures. This would also affect Bristol, which should and must bring a few good products from its pipeline onto the market in the next few years. The acquisition of Karuma together with the approval of KarXT has provided a brief boost, but is not enough to compensate for the expiry of patent protection for Revlimid, Opdivo and especially Eliquis in the next few years. They account for over USD 12 billion of sales and patent protection expires in the EU in 2026 and in the US in 2028. This does not mean that Eliquis will no longer be sold, but a not insignificant proportion is likely to be lost to generics. In addition, CMS has already negotiated price reductions of 56% for 2026. Coupled with the political uncertainties, I have taken the money with me for the time being and will wait and see. I still have to deal with $NOVO B (-5.1%) ...., which is currently the biggest loss-maker in my portfolio with a drop of almost 17%.
Please let me know your assessment of the market in this sector.
Hi guys, I am looking for a high dividend payer for my portfolio that pays out monthly, preferably with a stable price and not a sinking ship like $WBA (+0.14%) do you have some ideas 💡 for me?
The dividend should be at least 8%. Lg
WALGREENS $WBA (+0.14%) IN TALKS TO GO PRIVATE WITH SYCAMORE PARTNERS – WSJ
Walgreens $WBA is reportedly in advanced talks to sell itself to private equity firm Sycamore Partners in a deal that could close early next year.
Once valued at over $100B in 2015, Walgreens now has a market cap of just $7.5B after pressures on its pharmacy and retail businesses sent shares down ~70% YTD.
Sycamore, known for retail investments, may sell parts of Walgreens or bring in partners post-acquisition. This follows Walgreens' struggles with thin pharmacy margins, retail competition, and the fallout from its 2015 Boots acquisition.
The deal would mark a major shakeup for the 120-year-old company with 12,000+ stores across the U.S., Latin America, and Europe.
Top creators this week